Close Menu

NEW YORK – Exact Sciences announced today that it has entered into a deal to acquire Genomic Health for $2.8 billion in cash and stock.

In a separate announcement, the company reported its second quarter earnings rose 94 percent year over year, due to a 93 percent increase in testing volumes from its Cologuard colorectal cancer diagnostic.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.